Cosegregation of gastrointestinal ulcers and schizophrenia in a large national inpatient discharge database: Revisiting the "brain-gut axis" hypothesis in ulcer pathogenesis

Journal of Investigative Medicine

Volumn 55, Issue 6, 2007, Pages 315-320

  Ozdemir, Vural ^a   Jamal, M Mazen ^b   Osapay, Klara ^b   Jadus, Martin R ^b   Sandor, Zsuzsanna ^b   Hashemzadeh, Mehrtash ^b   Szabo, Sandor ^b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b VA LONG BEACH HEALTHCARE SYSTEM   (United States)

Author keywords

Association study; Brain gut axis; Dopamine; Drug targets; Gastrointestinal ulcer; Naturalistic design; Schizophrenia

Indexed keywords

ADULT; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DIGESTIVE SYSTEM ULCER; DISEASE ASSOCIATION; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATHOGENESIS; SCHIZOPHRENIA; UNITED STATES;

HELICOBACTER PYLORI; NICOTIANA TABACUM;

EID: 36749020653     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: 10.2310/6650.2007.00014     Document Type: Article

References (27)

1. Szabo S, Chen L, Deng X, et al. Why gastrointestinal ulcers develop and do not heal. In: Mozsik G, editor. Discoveries in gastroenterology: from basic research to clinical perspectives. 1960-2005. Budapest: Akademiai Kiado; 2006. p. 399-443.
2. Landsberg L, Berardino MB, Silva P. Metabolism of 3-H-L-dopa by the rat gut: in vivo evidence for glucuronide conjugation. Biochem Pharmacol 1975;24:1167-74.
3. Christensen NJ, Brandsborg O. Dopamine in human gastric juice determined by a sensitive double-isotope-derivative technique. Scand J Clin Lab Invest 1974;34:315-20.
4. Szabo S. Dopamine disorder in duodenal ulceration. Lancet 1979;2:880-2.
5. Hernandez DE, Adcock JW, Orlando RC, et al. Prevention of stress-induced gastric ulcers by dopamine agonists in the rat. Life Sci 1984;35:2453-8.
6. Glavin GB. Activity of selective dopamine DA1 and DA2 agonists and antagonists on experimental gastric lesions and gastric acid secretion. J Pharmacol Exp Ther 1989;251:726-30.
7. Li ZS, Pham TD, Tamir H, et al. Enteric dopaminergic neurons: definition, developmental lineage, and effects of extrinsic denervation. J Neurosci 2004;24:1330-9.
8. Vaughan CJ, Aherne AM, Lane E, et al. Identification and regional distribution of the dopamine D(1A) receptor in the gastrointestinal tract. Am J Physiol Regul Integr Comp Physiol 2000;279:R599-609.
9. Li ZS, Schmauss C, Cuenca A, et al. Physiological modulation of intestinal motility by enteric dopaminergic neurons and the D2 receptor: analysis of dopamine receptor expression, location, development, and function m wildtype and knock-out mice. J Neurosci 2006;26:2798-807.
10. Szabo S, Reynolds ES. Structure-activity relationships for ulcerogenic and adrenocorticolytic effects of alkyl nitriles, amines, and thiols. Environ Health Perspect 1975;11:135-40.
11. Szabo S, Selye H. Duodenal ulcers produced by propionitrile in rats. Arch Pathol 1972;93:390-1.
12. Selye H, Szabo S. Experimental model for production of perforating duodenal ulcers by cysteamine in the rat. Nature 1973;244:458-9.
13. Szabo S. Animal model of human disease. Duodenal ulcer disease. Animal model: cysteamine-induced acute and chronic duodenal ulcer in the rat. Am J Pathol 1978;93:273-6.
14. Szabo S, Cho CH. From cysteamine to MPTP: structure-activity studies with duodenal ulcerogens. Toxicol Pathol 1988;16:205-12.
15. Szabo S, Brown A, Pihan G, et al. Duodenal ulcer induced by MPTP (1-methyl-4-phenyl-1,2,36-tetrahydropyridine). Proc Soc Exp Biol Med 1985;180:567-71.
16. Marshall F, Szabo S. Correlation between ulcerogenic and neurotoxic effects of 1-methyl-4-phenyl-1,2,36-tetrahydropyridine (MPTP) and its reduced derivative in rats. Gastroenterology 1987;92:2062.
17. Abi-Dargham A. Do we still believe in the dopamine hypothesis? New data bring new evidence. Int J Neuropsychopharmacol 2004;7Suppl 1:S1-5.
18. Kobayashi M, Iaccarino C, Saiardi A, et al. Simultaneous absence of dopamine D1 and D2 receptor-mediated signaling is lethal in mice. Proc Natl Acad Sci U S A 2004;101:11465-70.
19. Nationwide Inpatient Sample (NIS), Healthcare Cost and Utilization Project, Agency for Healthcare Research and Quality (2002). Available at http://www.ahrq.gov/data/hcup- (Accessed August 13, 2007).
20. Jamal MM, Yoon EJ, Saadi A, et al. Trends in the utilization of endoscopic retrograde cholangiopancreatography (ERCP) in the United States. Am J Gastroenterol 2007. [Epub ahead of print].
21. World Health Organization. International Classification of Diseases (ICD), 2007 http://www.who.int/classifications/icd/en/ (Accessed on August 13, 2007).
22. Tamminga CA, Holcomb HH. Phenotype of schizophrenia: a review and formulation. Mol Psychiatry 2005;10:27-39.
23. Coyle JT. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol 2006;26:363-82.
24. Someya T, Sawamura K, Fukui N, Ozdemir V. The present state and the issue of pharmacogenetics/pharmacogenomics in clinical psychiatry. Japanese J Clin Psychopharmacol 2007;10:1403-7.
25. Ozdemir V, Williams-Jones B, Cooper DM, et al. Mapping translational research in personalized therapeutics: from molecular markers to health policy. Pharmacogenomics 2007;8:177-85.
26. Ozdemir V, Williams-Jones B, Graham JE, et al. Asymmetry in scientific method and limits to cross-disciplinary dialogue: towards a shared language and science policy in pharmacogenomics and human disease genetics. J Investig Med 2007;55:130-41.
27. Ozdemir V, Godard B. Crossing the blood brain barrier: Integration of scientific innovation with socio-ethical reflection. Psychiatric Times 2007 (in press).